COVID-19 clinical update #124 with Dr. Daniel Griffin

In COVID-19 clinical update #124, Dr. Griffin discusses the results of a variant vaccine booster trial, the neutralization of variant sub-lineages by Novavax, the CDC’s recommendation of Novavax’s COVID-19 vaccine in adults, Paxlovid in patients who are immunocompromised and hospitalized, and inhaled fluticasone for outpatient treatment.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Variant vaccine boosters trial (medRxiv)
• Novavax triggers neutralization of variant sub-lineages (bioRxiv)
• CDC recommends Novavax (CDC)
• Paxlovid in patients who are immunocompromised and hospitalized (The Lancet)
• Inhaled Fluticasone for outpatient treatment (medRxiv)
• PAXLOVID patient eligibility screening checklist (FDA)
• Remdesivir fact sheet for providers (Veklury) 
• Bebtelovimab fact sheet for providers (FDA)
• Contribute to FIMRC fundraiser at PWB
• Dr. Griffin’s treatment guide (pdf)
• Letters read on TWiV 921
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]